Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1)

The trial is an open-label, multi-center safety and efficacy trial of epcoritamab in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and Ritcher's Syndrome (RS). The trial consists of two parts, a dose escalation phase (phase Ib) and an expansion phase (phase II).

  • 0 views
  • 13 Mar, 2022
  • 18 locations
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

This phase I trial studies the side effects and best dose of duvelisib when given together with nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Duvelisib

tumor cells
monoclonal antibodies
beta-human chorionic gonadotropin
richter syndrome
cancer
  • 0 views
  • 20 Feb, 2022
  • 1 location
A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 in patients with Chronic Lymphocytic Leukemia (CLL) or Richter

richter syndrome
venetoclax
chronic lymphocytic leukemia
  • 0 views
  • 30 Dec, 2021
  • 2 locations
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that

obinutuzumab
monoclonal antibodies
richter syndrome
lymphoma
direct bilirubin
  • 0 views
  • 27 Jan, 2022
  • 1 location
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: Venetoclax R-EPOCH: Rituximab Etoposide Prednisone Vincristine Sulfate (Oncovin) Cyclophosphamide Doxorubicin Hydrochloride (Hydroxydaunomycin) R-CHOP: Rituximab Cyclophosphamide Vincristine …

  • 16 views
  • 28 Jan, 2022
  • 2 locations
A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Richter's syndrome (RS) is a life-threatening complication of chronic lymphocytic leukemia (CLL). It is associated with a switch in histopathology and biology, generally with a transformation of the original CLL clone to diffuse large B-cell lymphoma (DLBCL). The development of RS is accompanied by the onset of B symptoms, rapid …

  • 0 views
  • 15 Dec, 2021
  • 4 locations
Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

  • 1 views
  • 28 Feb, 2022
  • 11 locations
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

tg-1501
measurable disease
b-cell lymphoma
refractory b-cell non-hodgkin lymphoma
lymphoma
  • 13 views
  • 05 May, 2022
  • 9 locations
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, …

neutrophil count
etoposide
rituximab
cyclophosphamide
platelet count
  • 0 views
  • 03 Jan, 2022
  • 1 location
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome

richter syndrome
lymphoma
cancer
platelet count
diffuse large b-cell lymphoma
  • 21 views
  • 05 Mar, 2022
  • 6 locations